<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011375</article-id><article-id pub-id-type="publisher-id">ACM-38531</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_19776641.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  新型血栓与止血分子标志物在急性冠脉综合征中的研究进展
  Research Progress of Novel Thrombus and Hemostatic Molecular Markers in Acute Coronary Syndrome
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>哲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>齐</surname><given-names>微</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>悦</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>夜</surname><given-names>雪敏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邢</surname><given-names>延芳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学医学院，陕西 延安</addr-line></aff><aff id="aff3"><addr-line>延安大学附属东关分院检验科，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2487</fpage><lpage>2492</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    急性冠脉综合征是严重的心血管疾病，可并发恶性心律失常、急性心力衰竭和心脏破裂等，常可危及生命，是冠心病中的危重类型，早期诊断对疾病的治疗效果与后续恢复至关重要。本文就新型血栓与止血分子标志物在急性冠脉综合征的早期诊断做一综述。
    Acute coronary syndrome is a serious cardiovascular disease that can be complicated by malignant arrhythmia, acute heart failure, and heart rupture. It can often be life-threatening. It is a critical type of coronary heart disease. Early diagnosis is critical to the treatment effect and subsequent recovery of the disease. This article reviews the early diagnosis of acute coronary syndrome by new molecular markers of thrombosis and hemostasis. 
  
 
</p></abstract><kwd-group><kwd>急性冠脉综合征，血栓与止血分子标志物, Acute Coronary Syndrome</kwd><kwd> Thrombus and Hemostasis Molecular Markers</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>急性冠脉综合征是严重的心血管疾病，可并发恶性心律失常、急性心力衰竭和心脏破裂等，常可危及生命，是冠心病中的危重类型，早期诊断对疾病的治疗效果与后续恢复至关重要。本文就新型血栓与止血分子标志物在急性冠脉综合征的早期诊断做一综述。</p></sec><sec id="s2"><title>关键词</title><p>急性冠脉综合征，血栓与止血分子标志物</p></sec><sec id="s3"><title>Research Progress of Novel Thrombus and Hemostatic Molecular Markers in Acute Coronary Syndrome</title><p>Zhe Wang<sup>1</sup>, Wei Qi<sup>1</sup>, Yue Wang<sup>1</sup>, Xuemin Ye<sup>1</sup>, Yanfang Xing<sup>2*</sup></p><p><sup>1</sup>Yan’an University School of Medicine, Yan’an Shaanxi</p><p><sup>2</sup>Department of Laboratory Medicine, Dongguan Branch of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/9-1571659x5_hanspub.png" /></p><p>Received: Oct. 11<sup>th</sup>, 2020; accepted: Nov. 2<sup>nd</sup>, 2020; published: Nov. 9<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/9-1571659x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Acute coronary syndrome is a serious cardiovascular disease that can be complicated by malignant arrhythmia, acute heart failure, and heart rupture. It can often be life-threatening. It is a critical type of coronary heart disease. Early diagnosis is critical to the treatment effect and subsequent recovery of the disease. This article reviews the early diagnosis of acute coronary syndrome by new molecular markers of thrombosis and hemostasis.</p><p>Keywords:Acute Coronary Syndrome, Thrombus and Hemostasis Molecular Markers</p><disp-formula id="hanspub.38531-formula12"><graphic xlink:href="//html.hanspub.org/file/9-1571659x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/9-1571659x8_hanspub.png" /> <img src="//html.hanspub.org/file/9-1571659x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>急性冠脉综合征(acute coronary syndrome, ACS)是以冠状动脉粥样硬化斑块破裂或糜烂，继发完全或不完全闭塞性血栓形成为病理基础的一组临床综合征，包括不稳定型心绞痛(unstable anginapectoris, UA)、ST段抬高型心肌梗死(ST-elevation myocardial infarction, STEMI)及非ST段抬高型心肌梗死(non-ST-elevation myocardial infarction, NSTEMI)。研究证实，内皮细胞的损伤、纤溶–凝血系统的激活是诱发急性血栓形成、ACS发生重要条件 [<xref ref-type="bibr" rid="hanspub.38531-ref1">1</xref>]。目前，心肌标志物在临床上应用广泛，其局限性在于心肌细胞损伤后才能检测 [<xref ref-type="bibr" rid="hanspub.38531-ref2">2</xref>]。当出现心肌标志物改变时，心肌细胞已经发生了不可逆损伤甚至坏死，相较于心肌梗死的速度和损伤程度，给予临床医生的预警时间远远不够，无法进行早期诊断和临床抗栓药物的使用。如果在疾病早期发生阶段就能识别并给予及时干预，对减少心肌细胞损伤、限制梗死面积、预防再发栓塞、延长患者生命具有重要临床意义。</p><p>临床研究表明，斑块破裂伴随血栓形成是急性冠脉综合征的主要原因，急性心肌梗死的发病与动脉内血栓形成关系密切。在斑块破裂过程中，内皮细胞失去抗血栓形成的屏障作用，并通过细胞黏附因子的过度表达，使淋巴细胞在斑块内积聚，参与炎症反应。目前常用的凝血指标有凝血酶原时间(prothrombin time, PT)、活化部分凝血活酶时间(activated partial thromboplatin time, APTT)、凝血酶时间(thrombin time, TT)、D-二聚体(D-Dimer, DD)、纤维蛋白原降解产物(fibrin/fibrinogen degradation products, FDPs)等，对凝血系统的监测不够敏感，异常时凝血功能往往已严重紊乱。在血栓形成过程中，血管内皮细胞会释放或合成许多物质，其中血栓调节蛋白(TM)、凝血酶–抗凝血酶复合物(TAT)、纤溶酶-α<sub>2</sub>纤溶酶抑制物复合物(PIC)、组织纤溶酶原激活物–纤溶酶原激活物抑制剂-1复合物(t-PAI-C)是血栓形成过程中产生的血栓前状态分子标志物，这些凝血、纤溶标志物的检测有助于血栓性疾病患者的早期诊断及预防。</p><p>本研究对近年血栓标志物的研究进展作以下综述，为急性冠脉综合症的早期诊断及治疗提供新的思路。</p></sec><sec id="s6"><title>2. 新型血栓与止血标志物</title><sec id="s6_1"><title>2.1. 血栓调节蛋白(Thrombomodulin, TM)</title><p>TM是由血管内皮细胞合成、位于血管细胞膜表面的糖蛋白，可稳定表达于机体细胞膜表面和血浆中 [<xref ref-type="bibr" rid="hanspub.38531-ref3">3</xref>]。它与凝血酶结合发挥抗凝血激活作用，还是激活活化蛋白C (PC)的辅助因子。在血管内皮受到损伤时，TM容易游离到循环血液中，即血中TM浓度显示高值时，反映了血管内皮损伤。TM主要通过以下几个方面发挥抗凝作用：① TM是凝血酶的受体，其与凝血酶结合形成血栓调节蛋白–凝血酶-PC复合物通过抑制凝血酶的产生，减少纤溶抑制物(thrombin-activatable fibrinolysis inhibitor: TAFI)的激活，促进纤溶酶原激活物抑制剂的降解，发挥促纤溶作用；并且高浓度的TM会导致纤维蛋白溶解的上调，低浓度的TM对纤维蛋白溶解具有下调的调节作用 [<xref ref-type="bibr" rid="hanspub.38531-ref4">4</xref>]；② 通过与凝血酶形成复合物，使凝血酶丧失活化纤维蛋白原的能力；③ 血栓调节蛋白与凝血酶结合促进凝血酶活化蛋白C (PC)，活化的蛋白C (APC)在蛋白S (PS)的作用下，可以使凝血因子Va和因子VIIIa失活，并结合因子Xa，抑制Xa活化凝血酶原而发挥抗凝作用；④ 蛋白酶激活受体(PAR)与TM通过竞争凝血酶上的位点，可减少血小板的活化。 [<xref ref-type="bibr" rid="hanspub.38531-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.38531-ref6">6</xref>] 研究发现，血小板聚集功能亢进及血管内皮细胞损伤在ACS发病中起重要作用 [<xref ref-type="bibr" rid="hanspub.38531-ref7">7</xref>]。黄丽红 [<xref ref-type="bibr" rid="hanspub.38531-ref8">8</xref>] 等发现，随着病情进展TM浓度呈增高趋势，这也与其他国内外报道 [<xref ref-type="bibr" rid="hanspub.38531-ref9">9</xref>] 相符，说明TM浓度不但与冠心病发生有关，而且与冠心病的进展及并发症的发生相关，这可能因为TM浓度高反映冠状动脉损伤重，内皮细胞损伤范围大。即提示TM水平是反映冠心病患者内皮损伤的良好指标，也是评价冠状动脉硬化狭窄程度的指标 [<xref ref-type="bibr" rid="hanspub.38531-ref10">10</xref>]，其浓度可反映ACS的病变严重程度及冠脉病变范围，对ACS患者的预后有一定的指导意义。</p></sec><sec id="s6_2"><title>2.2. 血浆凝血酶–抗凝血酶复合物(TAT)</title><p>生理情况下，体内生成极少量凝血酶(thrombinT)很快会被抗凝血酶-III (antithrombin-III, AT-III)以1:1的比例结合生成TAT而灭活，以维持内环境的稳定，故很难直接检测凝血酶的含量，由此认为血浆TAT水平可以间接反映凝血酶的生成量，来衡量体内的高凝状态。凝血酶的血液半衰期极短，因此不能直接测定，而TAT的血液半衰期为3~15分钟而能够测定。TAT的显著增加说明机体内凝血系统被激活且处于高水平，提示血栓形成风险，可以较早反应人体凝血功能。Mair等发现,急性心肌梗死(Acute myocardial infarction, AMI)患者，TAT变化较心肌肌钙蛋白T (cTnT)和肌酸激酶-MB (CK-MB)、肌红蛋白等更为敏感 [<xref ref-type="bibr" rid="hanspub.38531-ref12">12</xref>]。高TAT的AMI患者可能有心肌大片的坏死 [<xref ref-type="bibr" rid="hanspub.38531-ref11">11</xref>]。因此，TAT水平有助于AMI早期诊断及预后判断。沈培辰 [<xref ref-type="bibr" rid="hanspub.38531-ref12">12</xref>] 等研究发现AMI患者组TAT水平明显高于正常对照组(P均&lt;0.01)，且比较溶栓前、治疗后6 h、12 h的TAT浓度发现，溶栓6hTAT的浓度比溶栓前比有所升高，而在溶栓12后下降，与国内外文献报道一致。还有研究发现 [<xref ref-type="bibr" rid="hanspub.38531-ref13">13</xref>]，凝血酶在AMI 发作时上升，溶栓后更高，这种升高可能是15%~25% AMI患者溶栓后发生再闭塞的重要原因，提示TAT可预测AMI患者溶栓治疗结果。综上所述，TAT的检测及动态观察有助于早期监测机体凝血系统的变化，对于AMI的早期诊断、治疗及预后判断都有重要的意义。</p></sec><sec id="s6_3"><title>2.3. 纤溶酶-α<sub>2</sub>纤溶酶抑制物复合物(PIC)</title><p>纤溶是健康人体的重要生理功能，与血液凝固存在着既矛盾又统一的动态平衡关系。当机体发生血栓时，纤溶系统被激活而发生血栓溶解，血流复通。PIC是由α<sub>2</sub>PI与血液中的纤溶酶以1:1结合形成的化合物，是忠实反映纤溶状态的极其有用的纤溶系统分子标志物。纤溶酶在血液中的半衰期极短而PIC半衰期为6小时，通过测定血中PIC的浓度能够了解采血时纤溶激活的程度。PIC代表纤溶系统激活，纤维蛋白在纤溶酶的作用下降解为FDP和D-D。在急性血栓形成条件下，纤维蛋白溶解系统被活化，其激活物PIC显著升高。吕永楠 [<xref ref-type="bibr" rid="hanspub.38531-ref14">14</xref>] 等试验表明，PIC对急性心肌梗死具有较高的诊断价值(AUC = 0.909)，提示PIC作为纤溶酶活化因子，具有较好的血栓形成诊断价值。急性心肌梗死患者存在再发血栓风险，心肌标志物在短时间内难以评估二次血栓风险，但PIC水平动态变化有助于临床医生在短时间内评估二次血栓形成的风险。</p></sec><sec id="s6_4"><title>2.4. 组织型纤溶酶原激活剂-纤溶酶原激活物抑制剂-1复合物(t-PAI-C)</title><p>纤维蛋白溶解可分为两个基本阶段：纤溶酶原的激活和纤维蛋白的降解。正常情况下，血浆中的纤溶酶以无活性的纤溶酶原形式存在。由血管内皮细胞释放到血液的组织型纤溶酶原激活剂(tissue plasminogen activator, t-PA)，是血液中纤溶酶原激活物的一种，是激活纤溶系统的主要物质，也是内源性对抗血栓形成的关键物质 [<xref ref-type="bibr" rid="hanspub.38531-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.38531-ref16">16</xref>]，与生理性抑制因子纤溶酶原激活物抑制剂-1 (PAI-1)迅速以1:1结合，形成组织型纤溶酶原激活剂-纤溶酶原激活物抑制剂-1复合物(t-PAI-C)，该复合物被认为是纤溶系统分子标志物，也是血管内皮细胞损害指标的分子标志物。t-PA释放能力降低可能与内源性血管内血栓形成防御功能受损有关 [<xref ref-type="bibr" rid="hanspub.38531-ref17">17</xref>]。当凝血在其他健康的血管中开始时，内皮细胞被激活并释放大量纤溶酶组织型纤溶酶原激活剂(t-PA)，在不可逆的组织损伤发生之前溶解血栓 [<xref ref-type="bibr" rid="hanspub.38531-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.38531-ref19">19</xref>]。当内皮功能受损时，t-PA释放减少 [<xref ref-type="bibr" rid="hanspub.38531-ref15">15</xref>]。在血栓形成过程中，血栓局部内皮细胞释放t-PA的速度和程度对于增加血栓溶解起着决定作用 [<xref ref-type="bibr" rid="hanspub.38531-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.38531-ref21">21</xref>]，决定着血栓是继续形成还是发生溶解。纤溶酶原激活及纤维蛋白降解的程度取决于局部t-PA的急性释放及其随后产生的抑制物之间的平衡，这种平衡是通过t-PA与PAI-1形成复合物实现的。这种纤溶系统失衡的存在，造成局部微血栓扩张，最终引起大动脉栓塞 [<xref ref-type="bibr" rid="hanspub.38531-ref22">22</xref>]。这种失衡在增加心肌梗死危险因素中有着重要作用。一项前瞻性研究发现AMI组与健康对照组、稳定型冠心病组相比t-PAI-C显著升高，但在发病30 d后，AMI组和稳定型冠心病组之间差异并不显著 [<xref ref-type="bibr" rid="hanspub.38531-ref23">23</xref>]。这反映了t-PAI-C有作为AMI早期诊断分子标志物的价值。几项前瞻性群组研究支持这样一个观点，即纤溶因子如PAI-1和t-PA的质量浓度可以预测AMI的未来趋势 [<xref ref-type="bibr" rid="hanspub.38531-ref24">24</xref>]。有研究表明内皮细胞的纤溶能力测定是一个强大的预测急性心血管事件风险的新方法 [<xref ref-type="bibr" rid="hanspub.38531-ref25">25</xref>]。血栓前状态和纤溶系统激活的检测可能是ACS患者重要的危险分层依据，并且这些测定可能有助于指导冠心病不稳定期的抗血栓治疗 [<xref ref-type="bibr" rid="hanspub.38531-ref26">26</xref>]。</p></sec></sec><sec id="s7"><title>3. 结语</title><p>在国家心血管病中心组织编撰的《中国心血管病报告2018》中 [<xref ref-type="bibr" rid="hanspub.38531-ref27">27</xref>]，指出目前我国心血管病现患人数约为2.9亿，死亡率居所有疾病首位，死亡人数占居民疾病死亡人数的一半，且患病率及死亡率仍处于上升趋势。据统计，2016年农村心血管病死亡占全部死亡的比率为45.50%，城市心血管死亡占全部死亡的比率为43.16%，即每5例死亡中就有2例死于心血管 [<xref ref-type="bibr" rid="hanspub.38531-ref28">28</xref>]，其中城市死亡率略有下降，农村则呈现了相反趋势，提示我国农村人群以及偏远地区的疾病基层防治工作不容小觑。目前，我国农村地区医疗仍处于落后水平，对于急性心肌梗死的介入治疗能力不足。因此，临床上对血栓分子标志物的监测，会给我们足够的时间采取有效措施，避免急性心肌梗死发生，而不是在梗死发生后挽救坏死的心肌细胞。新型血栓与止血分子标志物能够在心肌梗死亚急性阶段预测心肌梗死再发或猝死。这四种标志物在AMI患者血浆中的含量明显高于正常健康人群，可以作为早期检测动脉粥样硬化及血栓形成的分子标志物，同时标志物的含量在患者手术后明显降低，表明其可以用来检测治疗方法的有效性 [<xref ref-type="bibr" rid="hanspub.38531-ref29">29</xref>]。</p></sec><sec id="s8"><title>4. 展望</title><p>近年来，TM、TAT、PIC、t-PAI-C在冠心病早期诊断中的作用逐渐被认同，尤其在ACS的诊断中有一定的价值，但根据血栓标志物水平的动态变化制定相应的治疗方案及判断疗效还有待进一步研究，所以还需多种族人群的、更大规模的、多中心的研究加以论证，为ACS的早期诊断和防治提供依据。</p></sec><sec id="s9"><title>文章引用</title><p>王 哲,齐 微,王 悦,夜雪敏,邢延芳. 新型血栓与止血分子标志物在急性冠脉综合征中的研究进展Research Progress of Novel Thrombus and Hemostatic Molecular Markers in Acute Coronary Syndrome[J]. 临床医学进展, 2020, 10(11): 2487-2492. https://doi.org/10.12677/ACM.2020.1011375</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38531-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Hansson, G.K. (2005) Inflammation, Atherosclerosis, and Coronary Artery Disease. New England Journal of Medicine, 352, 1685-1695. &lt;br&gt;https://doi.org/10.1056/NEJMra043430</mixed-citation></ref><ref id="hanspub.38531-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">王琳. 血清H-FABP水平变化对急性心肌梗死早期诊断作用的初步分析[J]. 微循环学杂志, 2014, 24(2): 66-67.</mixed-citation></ref><ref id="hanspub.38531-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">董炤, 刘秀珍, 刘从彬, 等. 血栓调节蛋白的临床研究进展[J]. 安徽医药, 2010, 14(4): 383-384.</mixed-citation></ref><ref id="hanspub.38531-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Mosnier, L.O., Meijers, J.C. and Bouma, B.N. (2001) Regulation of Fibrinolysis in Plasma by TAFI and Protein C Is Dependent on the Concentration of Thrombomodulin. Thrombosis and Haemostasis, 85, 5-11.  
&lt;br&gt;https://doi.org/10.1055/s-0037-1612655</mixed-citation></ref><ref id="hanspub.38531-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Wu, Y.Z., Chang, L.H., Ren, H., et al. (2010) Changes of Thrombomodulin and Thrombomodulin Ala455Val Polymorphism(C14181) in Chinese Han Patients with Acute Cerebrovascular Diseases. International Journal of Cerebrovascular Disease, 18, 21-25.</mixed-citation></ref><ref id="hanspub.38531-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Tran, N.D., Wang, L., et al. (1998) Measurement of Thrombomodulin m RNA Expression in Brain Capillaries by Polymerase Chain Reaction. Thrombosis Research, 91, 191-197. &lt;br&gt;https://doi.org/10.1016/S0049-3848(98)00085-1</mixed-citation></ref><ref id="hanspub.38531-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Krumholz, H.M. (1997) Platelet Receptor Inhibition for Ischemic Syndromes. Journal Watch Cardiology, 338, 1498-1505.</mixed-citation></ref><ref id="hanspub.38531-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">黄丽红, 郭民, 侯纯荣, 孟眷. 急性冠脉综合征患者血栓调节蛋白水平及临床意义[J]. 中国医药导报, 2009, 6(28): 25-26.</mixed-citation></ref><ref id="hanspub.38531-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Uno, M., Tsuji, H., Watanabe, M., et al. (1989) Application of Thrombin Antithrombin &amp; Complex for Detecting a Latent Hypercoagulable State in Patients with Coronary Heart Disease. Japanese Circulation Journal, 53, 1185-1195.  
&lt;br&gt;https://doi.org/10.1253/jcj.53.1185</mixed-citation></ref><ref id="hanspub.38531-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">潘志红, 张江蓉, 袁惠敏, 等. 老年人血栓调节蛋白与冠状动脉病变的相关性研究[J]. 中国综合临床, 2007(12): 1059-1060.</mixed-citation></ref><ref id="hanspub.38531-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">吴方, 王学锋. 高凝状态患者止凝血分子标志物的检测及其临床意义[J]. 上海医学检验杂志, 2000, 15(3): 180-182.</mixed-citation></ref><ref id="hanspub.38531-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">沈培辰, 张代富, 王娟, 马兰. 急性心肌梗死患者血浆TAT变化的价值[J]. 实用全科医学, 2005, 3(6): 477-478.</mixed-citation></ref><ref id="hanspub.38531-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Giannitsis, E., Siemens, H.J., Mitusch, R., et al. (1999) Prothrombin Fragments F1+2, Thrombin Antithrombin &amp; Complex, Fibrin Monomers and Fibrinogen in Patients with Coronary Atherosclerosis. International Journal of Cardiology, 68, 269-274. &lt;br&gt;https://doi.org/10.1016/S0167-5273(98)00256-3</mixed-citation></ref><ref id="hanspub.38531-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">吕永楠, 任玮, 陈晶晶, 李晓艳. 急性心肌梗死患者血栓标志物水平变化及意义[J]. 微循环学杂志, 2017, 27(3): 43-46.</mixed-citation></ref><ref id="hanspub.38531-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kooistra, T., Schrauwen, Y., Arts, J., et al. (1994) Regulation of Endothelial Cell t-PA Synthesis and Release. International Journal of Hematology, 59, 233-255.</mixed-citation></ref><ref id="hanspub.38531-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Chandler, W.L., Trimble, S.L., Loo, S.C., et al. (1990) Effect of PAI-1 Levels on the Molar Concentrations of Active Tissue Plasminogen Activator (t-PA) and t-PA/PAI-1 Complex in Plasma. Blood, 76, 930-937.  
&lt;br&gt;https://doi.org/10.1182/blood.V76.5.930.930</mixed-citation></ref><ref id="hanspub.38531-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Pia, L., Niklas, B., Emma, L., Erik, U., Mia, M., Karin, W., Lena, K. and Sverker, J. (2013) Histone Deacetylase Inhibitors Stimulate Tissue-Type Plasminogen Activator Production in Vascular Endothelial Cells. Journal of Thrombosis and Thrombolysis, 35, 185-192. &lt;br&gt;https://doi.org/10.1007/s11239-012-0831-6</mixed-citation></ref><ref id="hanspub.38531-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Fox, K.A., Robison, A.K., Knabb, R.M., Rosamond, T.L., Sobel, B.E., et al. (1985) Prevention of Coronary Thrombosis with Subthrombolytic Doses of Tissue-Type Plasminogen Activator. Circulation, 72, 1346-1354.  
&lt;br&gt;https://doi.org/10.1161/01.CIR.72.6.1346</mixed-citation></ref><ref id="hanspub.38531-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Giles, A.R., Nesheim, M.E., Herring, S.W., Hoogendoorn, H., Stump, D.C., et al. (1990) The Fibrinolytic Potential of the Normal Primate Following the Generation of Thrombin in Vivo. Thrombosis and Haemostasis, 63, 476-481.  
&lt;br&gt;https://doi.org/10.1055/s-0038-1645069</mixed-citation></ref><ref id="hanspub.38531-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Oliver, J.J., Webb, D.J. and Newby, D.E. (2006) Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 2470-2479.  
&lt;br&gt;https://doi.org/10.1161/01.ATV.0000189309.05924.88</mixed-citation></ref><ref id="hanspub.38531-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Hrafnkelsdottir, T., Gudnason, T., Wall, U., et al. (2004) Regulation of Local Availability of Active Tissue-Type Plasminogen Activator in Vivo in Man. Journal of Thrombosis and Haemostasis, 2, 1960-1968.  
&lt;br&gt;https://doi.org/10.1111/j.1538-7836.2004.00948.x</mixed-citation></ref><ref id="hanspub.38531-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Salame, M.Y., Samani, N.J., Masood, I., et al. (2000) Expression of the Plasminogen Activator System in the Human Vascular Wall. Atherosclerosis, 152, 19-28. &lt;br&gt;https://doi.org/10.1016/S0021-9150(99)00441-4</mixed-citation></ref><ref id="hanspub.38531-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Shantsila, E., Montoro-García, S., Tapp, L.D., et al. (2012) Fibrinolytic Status in Acute Coronary Syndromes: Evidence of Differences in Relation to Clinical Features and Pathophysiological Pathways. Thrombosis and Haemostasis, 108, 32-40. &lt;br&gt;https://doi.org/10.1160/TH12-01-0011</mixed-citation></ref><ref id="hanspub.38531-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Lijnen, H.R. and Collen, D. (1996) Impaired Fibrinolysis and the Risk for Coronary Heart Disease. Circulation, 94, 2052-2054. &lt;br&gt;https://doi.org/10.1161/01.CIR.94.9.2052</mixed-citation></ref><ref id="hanspub.38531-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Robinson, S.D., Ludlam, C.A., Boon, N.A., et al. (2007) Endothelial Fibrinolytic Capacity Predicts Future Adverse Cardiovascular Events in Patients with Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 1651-1656. &lt;br&gt;https://doi.org/10.1161/ATVBAHA.107.143248</mixed-citation></ref><ref id="hanspub.38531-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Galvani, M., Ferrini, D., Ottani, F., et al. (1999) Early Risk Stratification of Unstable Angina/non-Q Myocardial Infarction: Biochemical Markers of Coronary Thrombosis. International Journal of Cardiology, 68, S55-S61.  
&lt;br&gt;https://doi.org/10.1016/S0167-5273(98)00292-7</mixed-citation></ref><ref id="hanspub.38531-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(3): 209-220.</mixed-citation></ref><ref id="hanspub.38531-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">高润霖, 张澍, 王增武, 等. 新中国成立七十年来我国心血管病学的发展[J]. 中国循环杂志, 2019, 34(9): 833-843.</mixed-citation></ref><ref id="hanspub.38531-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Negreva, M., Georgiev, S., Prodanova, K., et al. (2016) Early Changes in the Antithrombin and Thrombin-Antithrombin Complex in the Patients with Paroxysmal Atrial Fibrillation. Cardiology Research, 7, 89-94.  
&lt;br&gt;https://doi.org/10.14740/cr469w</mixed-citation></ref></ref-list></back></article>